Gene Holdings Inc. rises on 62% CR rate in Phase 2 NMIBC trial. Click to learn about ENGN and its gene delivery tech, market ...
“Identifying individuals at high risk for UTIs allows for more targeted treatment and care strategies, thereby enhancing patient safety.” — Yunlan Jiang, Chengdu University of Traditional Chinese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback